351 related articles for article (PubMed ID: 19025986)
1. Novel agents in myeloma: an exciting saga.
Mark T; Niesvizky R; Coleman M
Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
[No Abstract] [Full Text] [Related]
2. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
4. New drugs for multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
[No Abstract] [Full Text] [Related]
5. [Multiple myeloma -- therapy].
Jung W; Zettl F; Schroers R
Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
[No Abstract] [Full Text] [Related]
6. Multiple myeloma therapies.
Strobeck M
Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
[No Abstract] [Full Text] [Related]
7. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Rajkumar SV
Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
[No Abstract] [Full Text] [Related]
8. [Thalidomide treatment in multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
[No Abstract] [Full Text] [Related]
9. Novel therapies in myeloma.
Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
[TBL] [Abstract][Full Text] [Related]
10. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
12. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Takamatsu Y
Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
[No Abstract] [Full Text] [Related]
13. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
14. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
16. Frontline treatment of multiple myeloma in elderly patients.
Moreau P; Hulin C; Facon T
Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
[TBL] [Abstract][Full Text] [Related]
17. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
[TBL] [Abstract][Full Text] [Related]
18. New agents and approaches in the treatment of multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
[No Abstract] [Full Text] [Related]
19. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Yaqub S; Ballester G; Ballester O
Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
